Reversing into the shell corp. of Dublin, Ireland based Almah, Inc., the penny stock of Arch Therapeutics, Inc. (OTC: ARTH) is as live as their website is. Coming online over the weekend, traders can anticipate making an investment based on the possibility of a developed product, AC5™, which can control fluid leakage during surgery and trauma care. How will the ARTH stock alerts read once they are issued: “If successful, AC5™ could make surgery faster and safer. This means better surgical outcomes for potentially everyone, including you.” While it isn’t quite Farrow Tech and their drug called Parattin that was never in the 3rd stage of FDA approval to help premature babies develop properly, this penny stock actually has some money behind it already which is, at the very least, a starting point.
Our Next Pick Is Coming Soon! Click HERE To Make Sure You Don’t Miss Any Of Our Breaking Alerts!
ARTH Stock Quote
Market Cap: 34.41M
Last: 0.79 ▲ 0.19 (+31.67%)
Issued and Outstanding: 43,560,000
Looking for Hot Penny Stocks?
Click here To Receive FREE Penny Stock Alerts
The insiders are more the story for Arch Therapeutics than the proposed product they are developing. While Terrence W. Norchi, M.D. takes the spotlight as President and CEO of the company he co-founded in 2006, Avtar Dhillon, M.D. comes with the real resume traders want to see.
Dr. Dhillon, 52, has been a member of the Board of Directors of Arch Therapeutics since May 2011. Dr. Dhillon is the former President & CEO of Inovio Pharmaceuticals, Inc. (AMEX: INO). During his tenure at Inovio, nearly a decade, Dr. Dhillon successfully led the turnaround of the company through restructuring and acquisition of technology from several European and North American companies including merger with VGX Pharmaceuticals to develop a vertically integrated DNA vaccine development company with one of the strongest development pipelines in the industry. Additionally, $136 million in financing was arranged during his tenure as well as several licensing deals valued at over $200 million that has included global giants, Merck and Wyeth (now Pfizer).
But wait, it gets even better….
In addition to his current board member roles with Arch Therapeutics, OncoSec Medical Inc. (ONCS)(Chairman), Inovio (INO)(Chairman) and Stevia First, Corp. (STVF)(Chairman), Dr. Dhillon currently sits on the Board of Directors of BC Advantage Funds, the largest Venture Capital Corporation in British Columbia.
One indicator trader’s can use as a “spot price” for ARTH stock comes from Coldstream Summit Ltd. Back on April 19th, Coldstream purchased $250,000 worth of ARTH stock at $0.50 per share (500,000 shares) and could still purchase an additional $1,750,000 worth (3.5 million shares) at the same price of $0.50 per share or assist Arch Therapeutics in securing all or a portion of such $1,750,000 investment from alternate sources. A bargain of a deal, for every $1 invested, the investor(s) making such investment will get 2 shares of ARTH stock and a warrant to purchase 2 shares of ARTH stock with an exercise price of $0.75 per share with a term of 12 months.
About ARTH Stock
Arch Therapeutics, Inc. is a medical device company focused on developing polymers containing peptides intended to form gel-like barriers over wounds to stop or control bleeding.
Arch Therapeutics Trading History:
Once the deal is closed, acquiring Arch Therapeutics, an additional 20 million shares of ARTH stock are set to be issued to the current shareholders of biotech. Those looking for a summer play should keep ARTH on their list of penny stocks to watch. Looking back at ONCS and STVF, both of which more than doubled last year during their runs, there’s a great chance that this could be one the next $1 stocks to put traders into a higher tax bracket off the potential profits.
Here is your opportunity to subscribe to the Most Read Penny Stock Newsletter
If You Can’t Make Money With Us, You Shouldn’t Be Trading Penny Stocks
(We are 100% Anti-Spam and will never rent or sell your information)Share